Oregano essential oil (oral, carvacrol)
Strongly antimicrobial in vitro, small clinical signal for SIBO and gastrointestinal parasites; popular but evidence is preliminary.
Why
Oregano essential oil (Origanum vulgare), particularly the high-carvacrol Mediterranean chemotype, has been heavily marketed as a 'natural antibiotic'. In vitro evidence of antibacterial, antifungal and antiparasitic activity is genuinely strong. Clinical evidence is much smaller: Force 2000 open trial in intestinal parasites, Chedid 2014 in SIBO, and several small studies in oral and dental applications. No Cochrane review, no EMA monograph for oral antimicrobial use.
How it works
Carvacrol and thymol (volatile phenols) disrupt microbial cell membranes via interaction with the lipid bilayer, broad-spectrum activity against bacteria, fungi (including Candida) and parasites in vitro. Bioavailability and tissue distribution after oral dosing are not well characterised in humans.
Expected onset · Acute antimicrobial effect within days; SIBO endpoints over 4 weeks
How to take
Dosage
Standardised oil (60–80% carvacrol): 100–600 mg/day divided. Capsules typically deliver 60–180 mg per capsule.
Timing
Divided 2–3 times daily with food (to reduce GI irritation)
On the label
Origanum vulgare essential oil with stated carvacrol content (60–80% for high-potency products). Enteric-coated capsules reduce GI irritation. Distinct from Mediterranean cooking oregano.
Ideal for
Adults with suspected SIBO or intestinal dysbiosis exploring botanical antimicrobials under clinical guidance; topical antimicrobial use.
Safety
Evidence
In vitro and food-microbiology literature on carvacrol is substantial. Force 2000 open trial reported clearance of intestinal Blastocystis, Entamoeba and Endolimax in a small group. Chedid 2014 retrospective SIBO study included oregano-containing protocol with response comparable to rifaximin. Preliminary, RCTs exist in non-tier-1 journals but are small or short-duration. No Cochrane review, EMA monograph or EFSA-authorised claim covers the indication. Marketed claims often outpace human clinical evidence.
Preliminary, RCTs exist in non-tier-1 journals but are small or short-duration. No Cochrane review, EMA monograph or EFSA-authorised claim covers the indication.
- Force et al., Phytother Res 2000, inhibition of enteric parasites by emulsified oil of oregano in vivo (open trial)
- Chedid et al., Glob Adv Health Med 2014, herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth (retrospective comparison including oregano-containing protocol)
- Burt, Int J Food Microbiol 2004, essential oils: their antibacterial properties and potential applications in foods (review)
Where to get it
Shop Oregano essential oil (oral, carvacrol) on AmazonSponsored · As an Amazon Associate, Healicus earns from qualifying purchases.